A Phase 4 interventional study of LVEF 3 month and LVEF 4 month in Breast Cancer, sponsored by Ottawa Hospital Research Institute. Completed at 4 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Health services research
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 15th largest by enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2016, is one of 20 in phase 4, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 70+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18–90 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 121 across the 40 interventional studies, 171 across the 4 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
1 of the studies in Breast Neoplasms by Ottawa Hospital Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252726Ottawa Hospital Research InstituteEvaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Several large adjuvant trastuzumab trials have demonstrated improved overall survival in participants with early stage breast cancer, with a 33% decrease in risk of death. However, retrospective analyses of participant outcomes in these trials have demonstrated increased risk of cardiotoxicity (i.e damage to the heart) in a small number of patients (4-8%).
At this time, investigators are unable to predict which participants are at increased risk of cardiac-related treatment complications. Currently all patients receive regular cardiac imaging throughout their one year of trastuzumab treatment.
At this time, the optimal monitoring schedule for trastuzumab-related cardiotoxicity remains unknown, and several published consensus guidelines are currently in use as standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
Procedure: LVEF 3 month
cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
Procedure: LVEF 4 month
cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
LVEF Results
Changes in Left Ventricular Ejection Fraction (LVEF) results compared to baseline (by echocardiography or MUGA) throughout the course of trastuzumab based therapy. LVEF is measured as a percentage. The outcome is a change in LVEF percentage (%).
Time frame: Baseline to 1 year
Rates of Trastuzumab Delay and Discontinuation
The number of participants who had a delay and/or discontinuation in trastuzumab treatment. Data was collected from physicians following clinic visits and from patient electronic medical records.
Time frame: 1 year
Referral to Cardiology
The number of participants who were referred to cardiology. Data was collected from physicians following clinic visits, and from the patient's electronic medical record.
Time frame: 1 year
Rate of Cardiac Events
The number of participants who experienced a decrease in ejection fraction (EF), congestive heart failure, or other cardiac events within the 1 year of study. Examples of other cardiac events include change in blood pressure, chest pain/shortness of breath, or irregular heartbeat. Data was collected/reported from physicians following clinic appointments, and from the patient's electronic medical record.
Time frame: 1 year
| Milestone | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| Started | 100 | 100 |
| Completed | 98 | 97 |
| Not completed | 2 | 3 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Participant decision | 0 | 2 |
| Milestone | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| Started | 98 | 97 |
| Completed | 90 | 88 |
| Not completed | 8 | 9 |
| Withdrew: Reason = lvef | 2 | 2 |
| Withdrew: Protocol violation | 2 | 6 |
| Withdrew: Metastatic disease | 3 | 0 |
| Withdrew: Location | 1 | 1 |
Changes in Left Ventricular Ejection Fraction (LVEF) results compared to baseline (by echocardiography or MUGA) throughout the course of trastuzumab based therapy. LVEF is measured as a percentage. The outcome is a change in LVEF percentage (%).
| LVEF Percentage (%) | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| LVEF Results | -8 (-26 to 17) | -6 (-33 to 10) |
The number of participants who had a delay and/or discontinuation in trastuzumab treatment. Data was collected from physicians following clinic visits and from patient electronic medical records.
| Participants | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| Delay | 9 | 2 |
| Discontinuation | 2 | 7 |
The number of participants who were referred to cardiology. Data was collected from physicians following clinic visits, and from the patient's electronic medical record.
| Participants | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| Referral to Cardiology | 12 | 12 |
The number of participants who experienced a decrease in ejection fraction (EF), congestive heart failure, or other cardiac events within the 1 year of study. Examples of other cardiac events include change in blood pressure, chest pain/shortness of breath, or irregular heartbeat. Data was collected/reported from physicians following clinic appointments, and from the patient's electronic medical record.
| Participants | LVEF 3 Month | LVEF 4 Month |
|---|---|---|
| Rate of Cardiac Events | 31 | 24 |
Collected over All-cause mortality was monitored for 12 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LVEF 3 Month | 0/98 (0%) | — | — |
| LVEF 4 Month | 0/97 (0%) | — | — |
| Age, Continuous(years) | LVEF 3 Month | LVEF 4 Month | Total |
|---|---|---|---|
| Mean | 55.4 ± 11.4 | 54.8 ± 11.3 | 55.1 ± 11.4 |
| Sex: Female, Male(Participants) | LVEF 3 Month | LVEF 4 Month | Total |
|---|---|---|---|
| Female | 98 | 97 | 195 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | LVEF 3 Month | LVEF 4 Month | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Baseline Left Ventricular Ejection Fraction (LVEF)(LVEF Percentage (%)) | LVEF 3 Month | LVEF 4 Month | Total |
|---|---|---|---|
| Median | 65 (54 to 82) | 64 (54 to 76) | 65 (54 to 82) |
| Anthracycline-based chemotherapy(Participants) | LVEF 3 Month | LVEF 4 Month | Total |
|---|---|---|---|
| Count of participants | 53 | 50 | 103 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jun 2016, a primary completion of May 2020 and a completion of Jul 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2025, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute →